TLE family member 2, transcriptional corepressorGenealiases: ESG · ESG2 · GRG2
Q-omics provides the consensus-scored TLE2 profile across patient tissues and cancer cell-line models. TLE2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, TLE2 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, TLE2 RNA expression shows 18,526 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight PAAD, HNSC, and TGCT as cancer lineages where TLE2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TLE2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TLE2 survival associations across molecular data types. TLE2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TLE2 RNA expression–survival associations across cancer types. High TLE2 expression shows unfavorable associations in ACC and UCS, but favorable associations in PAAD, UCEC, BLCA and LUAD. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for TLE2 RNA expression.
This table summarizes TLE2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TLE2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TLE2 shows lower tumor expression in HNSC, KIRC, BLCA, LUSC and BRCA and higher tumor expression in LIHC. The HNSC box plot shows higher TLE2 RNA expression in normal versus tumor tissue (log2 FC = −2.264, t-test p < 0.001).
This table shows molecular features associated with TLE2 in patient tissues and cancer cell lines. In patient samples, TLE2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TLE2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
